Zevalin, Bexxar Off-Label Coverage Decision Affirms Status Quo

Medicare contractors will retain the discretion to determine when to cover Biogen Idec's Zevalin and GlaxoSmithKline's Bexxar for off-label use in non-Hodgkin's lymphoma under a proposed coverage determination issued by the Centers for Medicare & Medicaid Services May 4